One moment
We’re getting things ready for you.
Muscle Growth & Recovery
Wolverine (Valkyr) Peptide Blend Guide
Learn more about Wolverine, including what it is, how it works, what it has been studied for, safety considerations, and how clinician-supervised treatment works through ElliotMeds.
Prescription requires licensed-provider review. No guaranteed outcomes.
Ready to get started? View Wolverine (Valkyr) pricing, dosage options, and start a provider chart review on the treatment page.
View Treatment OptionsWolverine (also referenced as Valkyr) is a compounded recovery blend pairing BPC-157 and TB-500. This page is educational and not medical advice.
Last updated: July 2, 2026
What Is Wolverine (Valkyr)?
Wolverine combines two peptides discussed in tissue-repair research: BPC-157 (a gastric-juice-derived synthetic peptide) and TB-500 (a fragment related to thymosin beta-4). It is framed as a clinician-supervised recovery-support blend and is not FDA-approved, nor a proven injury treatment.
How It Works
BPC-157 is studied in preclinical soft-tissue and gastrointestinal models; TB-500 is commonly described via thymosin beta-4 biology, with claims often inferred from thymosin beta-4 research. Human evidence for this exact blend is limited, and the combined mechanism is not an established clinical effect.
What It’s Studied For
BPC-157 and thymosin beta-4/TB-500-related peptides have been studied mainly in preclinical models of tissue repair, angiogenesis, wound healing, and inflammation. Thymosin beta-4 itself has more published wound-healing research than TB-500 fragment products, but TB-500 remains unapproved and not well validated for human orthopedic outcomes. Neither component is FDA-approved for these uses.
Regulatory Status
The FDA has flagged BPC-157 in its 503A bulk-substance review (Category 2, safety concerns); BPC-157 and TB-500-related substances have both been part of FDA compounding-safety discussions, and both are prohibited for athletes under the WADA framework. Compounding availability is subject to that status.
What to Expect
Use is provider-directed only; no outcome or timeline is promised. It does not replace orthopedic evaluation, imaging, physical therapy, post-surgical instructions, or treatment for acute injury.
Preferred Starting Options / Dosing Notes
Many patients begin with a lower starting option so a licensed clinician can evaluate tolerance, medical history, goals, and safety factors before any adjustments are considered. The starting option shown below is informational and reflects available program data, not self-directed dosing instructions. Final medication, dose, frequency, and treatment plan are determined by a licensed clinician.
Average starting option
- 5 mL
Available options
- 5 mL
Provider note: Do not change dose, frequency, or route of use unless directed by your clinician.
Safety Considerations
- Human safety data are limited and long-term effects unknown.
- Concerns include injection-site reactions, immunogenicity, and product purity/sterility, plus the added uncertainty of combining two unapproved peptides.
- No peptide is "safe" without qualification.
Important note
Some treatments may involve compounded medications when prescribed by a clinician. Compounded medications are not FDA-approved. The FDA does not evaluate compounded medications for safety, effectiveness, or quality before marketing.
Who Is Not a Candidate
A clinician reviews injury and surgical history, immune status, cancer history, pregnancy status, medications, and allergies before considering Wolverine, and may determine it is not appropriate.
How It Compares
Compared with BPC-157 or TB-500 alone, the blend combines two preclinical-evidence peptides, increasing uncertainty and additive-risk considerations. None is presented as superior.
Frequently Asked Questions
Is Wolverine FDA-approved?
No — neither component is FDA-approved for these uses, and BPC-157 is FDA-flagged (Category 2).
What is in it?
BPC-157 and TB-500.
What are the risks?
Injection-site and immune reactions, purity/sterility concerns, and the added uncertainty of a two-peptide stack.
Does payment guarantee a prescription?
No — a licensed clinician decides.
References
- Peer-reviewed preclinical literature on BPC-157 and thymosin beta-4/TB-500 (PubMed)
- FDA compounding-safety communications
- WADA Prohibited List
Disclaimer
Although the information on this page is based on available educational research and product information, it is provided for informational purposes only and is not medical advice. Treatment decisions, medication selection, dosing, and eligibility are determined by a licensed clinician after review. Not all patients are candidates, and individual results may vary. Use medications only as directed by your clinician.
Continue learning
Next step
Ready to start a provider chart review?
Begin by reviewing the treatment option and completing the secure provider chart review process.